|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cardiovascular autonomic neuropathy clinical manifestations显示文摘 | Raelene E Maser M James L | 2005 | maser and lenhard2005，29，10： | 1 |
| 2 | Rel/NF-k Btranscription factors: key Mediators of B-cell activation 显示文摘 | Raffi G Raelene G Mathis G at al | 2000 | Immunol Rev2000，176，1： | 1 |
| 3 | Prognancy cimplications andoutcomes among overweight and obese nulliparous women显示文摘 | Raelen MJ Bukusi EA Lambe M | 2001 | AmJ Public Henltn2001，91，3： | 1 |
| 4 | Continuous subcutaneous insulin infusion(CSⅡ)in patient with type2 diabetes显示文摘 | Lenhard MJ Raelene E | 2000 | Diabetes2000，50，12： | 1 |
| 5 | Continuous subcutaneous insulin infusion (CSⅡ) in patients with type Ⅱ diabetes 显示文摘 | Lenhard MJ Raelene E | | Diabetes Z000 50 (2)0，1837，： | 1 |
| 6 | Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop显示文摘 | Barbara Toffoli Raelene J. Pickering Despina Tsorotes Bo Wang Stella Bernardi Phillip Kantharidis Bruno Fabris Giorgio Zauli Paola Secchiero Merlin C. Thomas | 2011 | Atherosclerosis2011，，1： | 1 |
| 7 | Continuous subcutaneous insulin infusion(CSl]) in patient with type 2 diabetes显示文摘 | Lenhard MJ Raelene E | 2000 | Diabetes2000，50，12： | 1 |
| 8 | Continuous subcutaneous insulin infusion (CS I I) in patient with type 2 diabetes显示文摘 | Lenhard MJ Raelene E | 2000 | Diabetes2000，50，12： | 1 |
| 9 | Rel/NF-NF-KB tRNAscription factor: key mediators of B-cell activation 显示文摘 | Raffi G Raelene G Mathis G | 2000 | Immunol Rev2000，176，1： | 1 |
| 10 | Prognancy cimplica tions and outcomes among overweight and obese nullipa rous women显示文摘 | Raelen MJ Bukusi EA Lambe M | 2001 | Am J Public Henltn2001，91，3： | 1 |
| 11 | Diabetic Autonomic Neuropathy显示文摘 | Aaron I Braxton D Raelene E | 2003 | Diabetes Care2003，26，： | 1 |
| 12 | The Association Between Cardiovascular Autonomic Neuropathy and Mortality in Individuals With Diabetes显示文摘 | Raelene E Aaron I Braxton D | 2003 | Diabetes Care2003，26，： | 1 |
| 13 | Continuous subcutaneous insulin infusion (CSII)in patient with type 2 diabetes显示文摘 | Lenhard MJ Raelene E | 2000 | Diabetes2000，50，2： | 1 |
| 14 | Rel/NF- NF- кB transcription factors: key mediators of B - cell activation显示文摘 | Raffi G Raelene G Mathis G | 2000 | Immunol Rev2000，176，1： | 1 |
| 15 | Rel/ NF-KB transcription factors:key mediators of B-cell activation 显示文摘 | Raffi G Raelene G Mathis G | 2000 | Immunol Rev2000，176，1： | 1 |
| 16 | Prognancy cimplications and outcomes among overweight and obese nulliparous women显示文摘 | Raelen MJ Bukusi EA Lambe M | 2001 | Am J Public Henltn2001，91，3： | 1 |
| 17 | NF-KB transcription fac- tors : Key mediators of B-cell activation 显示文摘 | Raffi G Raelene G Mathis G | 2000 | Inununo! Rev2000，176，1： | 1 |
| 18 | B Cell Growth Is Controlled by Phosphatidylinosotol 3-Kinase-Dependent Induction of Rel/NF-κB Regulated c-myc Transcription显示文摘 | Raelene J Grumont Andreas Strasser Steve Gerondakis | 2002 | Molecular Cell2002，，6： | 1 |
| 19 | Review: Cardiovascular Autonomic Neuropathy Due to Diabetes Mellitus: Clinical Manifestations, Consequences, and Treatment显示文摘 | Raelene E. Maser M James Lenhard | 2005 | The Journal of Clinical Endocrinology & Metabolism2005，，10： | 1 |
| 20 | From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress显示文摘Glioblastoma,a rare,and highly lethal form of brain cancer,poses significant challenges in terms of therapeutic resistance,and poor survival rates for both adult and paediatric patients alike.Despite advancements in brain cancer research driven by a technological revolution,translating our understanding of glioblastoma pathogenesis into improved clinical outcomes remains a critical unmet need.This review emphasises the intricate role of receptor tyrosine kinase signalling pathways,epigenetic mechanisms,and metabolic functions in glioblastoma tumourigenesis and therapeutic resistance.We also discuss the extensive efforts over the past two decades that have explored targeted therapies against these pathways.Emerging therapeutic approaches,such as antibody-toxin conjugates or CAR T cell therapies,offer potential by specifically targeting proteins on the glioblastoma cell surface.Combination strategies incorporating protein-targeted therapy and immune-based therapies demonstrate great promise for future clinical research.Moreover,gaining insights into the role of cell-of-origin in glioblastoma treatment response holds the potential to advance precision medicine approaches.Addressing these challenges is crucial to improving outcomes for glioblastoma patients and moving towards more effective precision therapies. | Brittany Dewdney Misty RJenkins Sarah ABest Saskia Freytag Krishneel Prasad Jeff Holst Raelene Endersby Terrance GJohns | 2023 | Signal Transduction and Targeted Therapy2023，8，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员